Leading the Way in Life Science Technologies

GEN Exclusives

More »

Nov. 1, Vol. 26, No. 19

    • Point of View

      • Biotech Production Is Blooming in the Tropics
      • Fruits and flowers are not the only things blooming in the tropics. At the invitation of the U.S. State Department, I presented a series of lectures and briefings in the Philippines about an exciting advance in agricultural biotechnology: biopharmin ... more »
    • Feature Articles

      • Antibody Engineering Methods Advance
      • Antibody engineering is moving into its fourth decade, a stage of maturity that emphasizes both the success and the challenges of the discipline. One problem that antibody-engineering companies have long struggled with is the host immune response to ... more »
      • BioMarket Trends
      • The protein therapeutics industry got its start in early 1980s with the launch of recombinant insulin. Since then, the sector has undergone a rapid metamorphosis with the introduction of innovative new therapies like interferons and interleukins in ... more »
      • Can Pharma & Biotech Foil Counterfeiting?
      • Gail Dutton
      • Despite a downturn in FDA investigations into counterfeiting, concerns within the industry have actually increased, fueled by higher threat levels, the value of the products, and their sheer numbers. “Globally, the problem is getting worse,” accordi ... more »
      • Multidisciplinary Approach to RNAi
      • Encompassing molecular genetic, biological, and mathematical approaches, functional genomics is designed to study all genes or proteins simultaneously and systematically. Using the information provided by structural genomics, functional genomics att ... more »
      • Novel Vaccines Expand Potential Markets
      • The vaccine industry is a hotbed of activity. News of vaccines moving through the clinical pipeline and reaching the market, novel vaccine and viral vector technology emanating from industry and academia, and new disease targets, immunization strate ... more »
      • Outsourcing Can Add Capacity & Expertise
      • Outsourcing is no longer an option but is essential for pharmas that want to stay competitive was the dominant sentiment expressed by speakers at the recent “PABORD” meeting in London. “This is not a new trend,” said Arvind Mathur, Ph.D., external r ... more »
      • Small Molecule Drugs
      • Small molecules are experiencing renewed interest in drug development, exemplified by the “Biotech for Small Molecule Therapeutics” section during “BioFine USA” held recently. Presenters shared their business and biological strategies, which include ... more »
    • Legal Affairs

      • Maximizing the Value of Biotech Patents
      • Biotechnology and pharmaceutical patents often reach their maximum value toward the end of their term when the inventions described in the patents have matured from the laboratory through product development, clinical trials, and regulatory approval ... more »
    • Wall Street BioBeat

      • Third Quarter Life Science Sector Review
      • We begin our evaluation of third-quarter activity with the Mark Twain quotation, “The report of my death has been exaggerated,” as it may appropriately characterize the trends noted in our second-quarter sector assessment. No Chicken Little, we now ... more »
    • Tutorials

      • Multiparametric Assays on Individual Cells
      • Cell culture samples consisting of multiple cells provide only an average response rate to manipulation. Whole cell populations thereby miss unique responses of cell subpopulations. Scientists could benefit from the ability to study each cell indivi ... more »
      • Navigating the Postpreservation Viability Fog
      • As we proceed into the decade of cell therapy, we now recognize the critical need for the time management of cellular products. Many processes aimed at developing a cell therapy product are vastly different but all require preservation as an enablin ... more »
      • RNAi Libraries for Functional Genomics
      • The RNAi mechanism provides researchers with the ability to specifically silence the expression of individual genes based on sequence-specific degradation of a selected mRNA population in the cell to prevent protein synthesis. The method can be quit ... more »
    • Corporate Profile

      • GenoLogics Automates Omics for Labs
      • Pharmaceutical and biotechnology companies generate enormous amounts of complex scientific data from proteomics, genomics, and metabolomics research, which they hope to mine for new drug targets. The management and integration of such data can be ac ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »